All Courses
>
American Journal of Psychiatry
>
Courses by Date
>
2008
>
AJP CME Course for January 2008: Efficacy of Sibutramine for the Treatment of Binge Eating Disorder: A Randomized Multicenter Placebo-Controlled Double-Blind Study
AJP CME Course for January 2008: Efficacy of Sibutramine for the Treatment of Binge Eating Disorder: A Randomized Multicenter Placebo-Controlled Double-Blind Study
Information to Participants
OBJECTIVES. After evaluating a specific journal article, participants should be able to demonstrate an increase in their knowledge of clinical medicine. Participants should be able to understand the contents of a selected research or review article and to apply the new findings to their clinical practice.
PARTICIPANTS. This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.
EXPLANATION OF HOW PHYSICIANS CAN PARTICIPATE AND EARN CREDIT. In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the CME quiz and submit your evaluation and study hours (up to 1 AMA PRA Category 1 CreditTM).
CREDITS. The APA designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Psychiatric Assocation (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Estimated Time to Complete Course: 1 hour
Begin date: January 1, 2008
End date: December 31, 2009
Information on Course
Title: Efficacy of Sibutramine for the Treatment of Binge Eating Disorder: A Randomized Multicenter Placebo-Controlled Double-Blind Study
Faculty: Denise E. Wilfley, Ph.D., Scott J. Crow, M.D., James I. Hudson, M.D., Sc.D., James E. Mitchell, M.D., Robert I. Berkowitz, M.D., Vicky Blakesley, M.D., Ph.D., B. Timothy Walsh, M.D.
Affiliation: Department of Psychiatry, Washington University School of Medicine (D.E.W); Department of Psychiatry, University of Minnesota (S.J.C.); the Department of Psychiatry, Harvard Medical School and Biological Psychiatry Laboratory, McLean Hospital (J.I.H.); Neuropsychiatric Research Institute, Fargo, N.Dak. (J.E.M.); Department of Psychiatry, Weight and Eating Disorders Program, University of Pennsylvania School of Medicine and the Department of Child and Adolescent Psychiatry, The Children’s Hospital of Philadelphia (R.I.B.); Abbott Laboratories (V.B.); New York State Psychiatric Institute, Columbia University Medical Center (B.T.W.)
Disclosures: Dr. Crow has received research support from Abbott Laboratories, Eli Lilly, and Ortho McNeill; he has also served as a consultant to Eli Lilly. Dr. Hudson has received research support from Eli Lilly, OrthoMcNeil, and Forest Laboratories; he has also served as a consultant to Eli Lilly and Pfizer. Dr. Blakesley is an employee of Abbott Laboratories. Dr. Walsh has received research support from Abbot Laboratories. Dr. Berkowitz has received scientific advisory panel payment and research grants from Abbott Laboratories Drs. Wilfley and Mitchell report no competing interests.
Discussion of unapproved or investigational use of products*: Yes
*APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.
Copyright © 2008 by American Psychiatric Publishing, Inc